ERBB2 and gastroesophageal junction adenocarcinoma: The median OS time reached 18 months in the SPOTLIGHT trial [13], which investigated the efficacy of first-line zolbetuximab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) in patients with claudin 18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative, unresectable metastatic gastric cancer or gastroesophageal junction adenocarcinoma.